Cotinga Pharmaceuticals Price/Book
Cos'è Price/Book di Cotinga Pharmaceuticals?
Price/Book di Cotinga Pharmaceuticals, Inc. è -116.24
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su TSXV rispetto a Cotinga Pharmaceuticals
Cosa fa Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Aziende con price/book simili a Cotinga Pharmaceuticals
- Black Iron ha Price/Book di -120.34
- HCA Healthcare ha Price/Book di -120.12
- Huntsman Exploration Inc ha Price/Book di -118.25
- Regeneus Ltd ha Price/Book di -117.67
- Changsheng International ha Price/Book di -117.65
- Sable Resources ha Price/Book di -117.24
- Cotinga Pharmaceuticals ha Price/Book di -116.24
- Astra ha Price/Book di -113.97
- A2Z Technologies Canada ha Price/Book di -112.65
- Taiga Motors ha Price/Book di -112.18
- Clean Power Hydrogen Plc ha Price/Book di -108.51
- Fabled Copper ha Price/Book di -105.66
- Astra Exploration Inc ha Price/Book di -102.83